![](/img/cover-not-exists.png)
Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
Kelly, Ronan J, Chung, Ki, Gu, Yu, Steele, Keith E, Rebelatto, Marlon C, Robbins, Paul B, Tavakkoli, Fatemeh, Karakunnel, Joyson J, Lai, Dominic W, Almhanna, KhaldounVolume:
3
Year:
2015
Language:
english
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1186/2051-1426-3-S2-P157
File:
PDF, 251 KB
english, 2015